Divis Laboratories Ltd (DIVISLAB)
₹9,780.00
Mkt cap
₹2.60L Cr
P/E ratio
87.10
P/B
15.50
Div yield
0.31%
ROE
16.50%
ROCE
22.00%
EPS (TTM)
₹112.28
Book value
₹631
52W range
5,648–9,865
Sector
Healthcare
Price history
Previous close
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients [1]
NSE DIVISLABBSE 532488
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−0.86% from high₹9,780
₹5,648+73.17% from low₹9,865
Current
₹9,780.00
Prev close
₹9,664.00
Day
+1.20%
Price performance
1D
+1.20%
1W
+9.27%
1M
+3.70%
3M
+24.82%
6M
+49.68%
1Y
+48.96%
YTD
+52.99%
Financials
Revenue, profit & margin
P/E ratio
87.1×
DIVISLAB is 153% above the sector median of 34.4×
DIVISLAB87.1×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,778 | 1,909 | 1,855 | 2,303 | 2,118 | 2,338 | 2,319 | 2,585 | 2,410 | 2,715 | 2,604 | 2,831 | 3,080 | |
| Expenses | 1,274 | 1,430 | 1,366 | 1,572 | 1,496 | 1,622 | 1,576 | 1,699 | 1,681 | 1,827 | 1,714 | 1,897 | 1,825 | |
| Operating Profit | 504 | 479 | 489 | 731 | 622 | 716 | 743 | 886 | 729 | 888 | 890 | 934 | 1,255 | |
| OPM % | 28% | 25% | 26% | 32% | 29% | 31% | 32% | 34% | 30% | 33% | 34% | 33% | 41% | |
| Other Income | 81 | 86 | 95 | 79 | 79 | 106 | 82 | 86 | 119 | 145 | 14 | 155 | 64 | |
| Interest | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 3 | 8 | 6 | 6 | 6 | |
| Depreciation | 93 | 95 | 95 | 95 | 97 | 99 | 99 | 107 | 112 | 113 | 118 | 120 | 133 | |
| Profit before tax | 492 | 469 | 489 | 713 | 604 | 722 | 726 | 864 | 733 | 912 | 780 | 963 | 1,180 | |
| Tax % | 28% | 26% | 27% | 25% | 29% | 29% | 19% | 23% | 26% | 24% | 25% | 22% | 24% | |
| Net Profit | 356 | 348 | 358 | 538 | 430 | 510 | 589 | 662 | 545 | 689 | 583 | 751 | 902 | |
| EPS in Rs | 13.41 | 13.11 | 13.49 | 20.27 | 16.20 | 19.21 | 22.19 | 24.94 | 20.53 | 25.95 | 21.96 | 28.29 | 33.98 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
7 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.20% · closed higher next day 29 of last 62
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26† | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 14 Aug '23◦ | 6 Nov '23◦ | 10 Feb '24◦ | 25 May '24◦ | 3 Aug '24◦ | 9 Nov '24◦ | 3 Feb '25◦ | 17 May '25◦ | 6 Aug '25 | 7 Nov '25 | 11 Feb '26 | 23 May '26◦ |
| Earnings day | −0.49% | −0.72% | +2.41% | +3.22% | −3.29% | −0.84% | +3.61% | +4.79% | −4.30% | −3.30% | +3.42% | −1.89% |
| +1 day | −2.03% | −0.45% | +1.32% | +6.54% | −3.28% | −2.34% | +4.07% | +2.75% | −4.33% | −2.79% | +0.15% | −1.95% |
| +5 days | −0.71% | +0.86% | +1.95% | +4.84% | −2.01% | −0.82% | +1.06% | +7.29% | −4.81% | −5.40% | +1.75% | −5.14% |
| +15 days | −0.61% | +8.04% | −4.65% | +10.72% | −1.78% | +5.15% | −2.68% | +5.63% | −4.33% | −5.91% | +3.06% | −2.53% |
| +30 days | −1.76% | +3.59% | −7.79% | +10.42% | +9.24% | −1.06% | −1.05% | +8.44% | −3.26% | −5.88% | −2.88% | −1.92% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 30 Per Share | 30.00 | 24 Jul '26 | 24 Jul '26 |
Results analysis
Shareholding
as of Sep 202651.87%Promoter
Promoters51.87%0.01
FIIs20.38%0.19
DIIs19.08%0.21
Public8.58%0.05
Government0.09%
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports15
Concall transcripts36
TranscriptAug 2026RECAug 2026TranscriptMay 2026TranscriptFeb 2026RECFeb 2026TranscriptNov 2025RECNov 2025TranscriptAug 2025TranscriptMay 2025TranscriptFeb 2025RECFeb 2025TranscriptNov 2024RECNov 2024TranscriptAug 2024RECAug 2024TranscriptMay 2024RECMay 2024TranscriptFeb 2024RECFeb 2024TranscriptNov 2023TranscriptNov 2023TranscriptAug 2023RECAug 2023TranscriptMay 2023
Credit ratings6
Announcements5
Board Meeting Intimation for Considering And Approving Unaudited Financial Results For Quarter And Half Year Ended September 30, 2026. 22 Oct - Board meets on November 7, 2026 to approve Q2FY27 standalone and consolidated results; trading window closes until November 9.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Oct - Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026Closure of Trading Window 30 Sep - Trading window closes from October 1, 2026 until 48 hours after Q2 FY26 results.Announcement under Regulation 30 (LODR)-Newspaper Publication 12 Sep - Newspaper Clippings - Special Window for transfer and dematerialisation of physical sharesShareholder Meeting / Postal Ballot-Scrutinizer''s Report 10 Aug